The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

Explore this paper's citation graph

Summary

Proof-of-concept clinical trials have shown that low-dose interleukin-2 specifically expands and activates TReg cell populations and thus can control autoimmune diseases and inflammation.

Type
review
Published
2015-04-17
Cited by
617
References
128

Keywords

Immunology, Inflammation, Effector, Immune system, Disease

References

Cited by

Related papers